Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z    
Office of Genomics and Disease Prevention  
Office of Genomics and Disease Prevention

 

HuGE Review

 

This HuGE Review was published with modifications in the American Journal of Epidemiology 2000 Jan 1; 151(1): 7-32.

Glutathione S Transferase Polymorphisms and Colorectal Cancer


by S.C. Cotton, L. Sharp, J. Little, and N. Brockton,

Epidemiology Group, Department of Medicine & Therapeutics, University of Aberdeen, Foresterhill House Annex, Foresterhill, Aberdeen, Scotland, AB25 2ZD 

July 27, 1999


HuGE Review

Internet Sites
Medical Literature Search


At-A-Glance

The genes GSTM1 (chromosome 1p13.3) and GSTT1 (22q11.2) code for cytosolic enzymes GST-mu and GST-theta respectively, which are involved in phase 2 metabolism. Both genes may be deleted. There is geographical and ethnic variation in genotype frequencies for both genes. In developed countries colorectal cancer (CRC) is the second most common cancer. CRC has been inconsistently associated with polycyclic aromatic hydrocarbons (PAHs) in diet and tobacco. Because GST enzymes are involved in PAH metabolism, it has been postulated that genotype may modify CRC risk associated with PAH exposure. No consistent associations between GSTM1 or GSTT1 genotype and CRC have been observed. However, most studies have methodological limitations. Few studies have investigated gene-environment interactions. No interactions between GSTM1 or GSTT1 genotype and smoking and CRC risk have been reported. One polyp study suggests an interaction between GSTM1 genotype and smoking. Two studies suggest increased disease risk in subjects with high meat intake and GST non-null genotype, contrary to the underlying hypothesis. One study suggests a strong inverse relationship between CRC and broccoli consumption, particularly in subjects GSTM1 null. These finding require confirmation. Methods for determining GSTM1 and GSTT1 genotype are well established. Population testing is not currently justified.

Gene

Four GST isoenzyme classes have been identified - alpha, mu, pi and theta (1). Here we consider the two types most investigated in relation to colorectal cancer – GSTM-mu and GST-theta . These are summarised in table 1.

The GSTM1 and GSTT1 genes code for the cytosolic enzymes GSTM-mu and GST-theta respectively. These enzymes are involved in the conjugation reactions in phase 2 metabolism of xenobiotics (1), catalysing reactions between glutathione and a variety of electrophilic compounds (2). It is thought that most GST substrates are xenobiotics or products of oxidative stress, including some environmental carcinogens (1). In particular, the enzymes detoxify the carcinogenic polycyclic aromatic hydrocarbons (PAHs) present in diet and tobacco smoke (3). They also conjugate isothiocyanates, which are potent inducers of enzymes that detoxify environmental mutagens (4), to glutathione thereby diverting the isothiocyanates from the enzyme induction pathway to excretion (5). It has been postulated that the GST enzymes and the genes encoding these may be involved in susceptibility to cancer (6).

The genes coding for the enzymes GST-mu and GST-theta are polymorphic. There are three alleles at the GSTM1 locus, located on chromosome 1p13.3: GSTM1 null – a deletion, GSTM1a and GSTM1b (6). GSTM1a and b differ by a substitution in one base pair. There is no evidence of functional differences between them (6). The GSTT1 locus is located on chromosome 22q11.2 and is, in some instances, deleted (6). For both GSTM1 and GSTT1, the hypothesised consequence of the null genotype is reduced, or no, conjugation activity. Evidence is lacking on whether heterozygosity in either GSTM1 or GSTT1 affects gene function.

Gene Variants

We searched Medline and EMBASE using the MeSH heading "glutathione transferase" and the textwords "GST" and "glutathione S transferase" for papers published between 1993 and 1998. We also searched the CDC Office of Genomics and Disease Prevention Medical Literature Search and reviewed reference lists in published articles. We identified relevant papers and critically appraised them. This section includes studies reporting genotype frequencies in a variety of groups of individuals without cancer.

The frequency of individuals who are homozygous for the GSTM1 null genotype is summarised in table 2 (7-78), and those homozygous for the GSTT1 null genotype in table 3 (8, 10, 11, 14, 29, 32, 35-37, 39, 47-49, 51-53, 55, 58, 59, 63, 65, 68, 73-75, 77, 78, 80-85). Many of the series were control groups in case-control studies of cancer. However, few could be described as truly population-based; therefore selection or participation biases may account for some of the variation between studies. Some of the studies have small numbers of participants. Ethnicity is not always straightforward to establish: this limits the generalisability from, for example, one "white" population to another (86).

GSTM1

In African populations, the frequency of the GSTM1 null genotype ranges from 23%-48%; in Asian populations from 33%-63%; and in European populations from 39%-62%.

Published data from the Americas relate only to studies carried out in the USA; the range of reported frequencies is 23%-62%. In African-Americans and blacks the range is 23-41%, and in whites 35%-62%. In the two studies of subjects of Asian origin, the range was 32%-53%, and in the three studies including Hispanic/Mexican-American subjects the range was 40%-53%.

In two Australian series the frequency is 51%-54%. The highest frequencies have been reported in studies involving small numbers of subjects from parts of the South Pacific – 64%-100% (13). These studies differed from the others in that Southern Blotting rather than PCR methods were used.

GSTT1

The range of frequencies of the GSTT1 null genotype is 16%-64% in Asia, with frequencies of 44% or higher being reported in China, Japan, Korea and the Singapore Chinese. Thus, in some Asian populations, it has been suggested that the frequency of GSTT1 null deletions is similar to that of GSTM1 null. However, in African, African-American and white populations, the frequencies of GSTT1 null are lower than for GSTM1 null. The range of frequencies in three African series is 15%-26%, and in Europe 10%-21%. As was the case for GSTM1, data from the Americas relate only to the USA, where the range of frequencies is 10%-36%. In whites the range is 15%-27%; in African-Americans and blacks 22%-29%; and in Mexican-Americans, based on two studies, 10%-12%. No data on Asian subjects in the US is available. In three groups in Australia, the frequency of GSTT1 null ranged from 9%-19%.

Concordance between genotype and phenotype

Individuals lacking GST-mu or GST-theta activity can be identified using phenotypic assays which classify individuals as active or inactive on the basis of a bimodal distribution. Use of PCR methods informs of the presence or absence of the GSTM1 or GSTT1 alleles. Several studies have investigated concordance between genotype and phenotype; this can be a means of determining whether the appropriate section of DNA coding for the particular phenotype has been identified.

Four studies in Europe and one in the USA have demonstrated concordances between GSTM1 genotype and GST-mu phenotype of 94% or greater (26, 33, 87-89). However, in one study in which genotype and phenotypic status was compared in 63 healthy Zimbabwean volunteers, concordance was lower – 84% (90). This may have been due to presence of (i) other mutations which affect protein expression, (ii) compounds in the diet that may affect protein levels, or (iii) mutations in the regions of the gene which bind to the primers during PCR but which do not affect enzyme activity (90). Genotyping methods developed in populations of European origin may slightly underestimate the proportion of African populations with GSTM1 null genotype (90).

In two small studies (82, 91) and one larger one (83) in northern European populations concordance between GSTT1 genotype and conjugator status (phenotype) in excess of 95% was found.

Disease

Worldwide in 1996, there were estimated to be 875,000 new cases of colorectal cancer (92). There is substantial geographical variation in incidence (Figure 1) (93). Epidemiologic evidence suggests that much of the geographical variation reflects variations in environmental or lifestyle exposures, perhaps acting with variations in genetic factors. In developed countries colorectal cancer is the second most common cancer, and in developing countries it ranks sixth most common in men and fifth in women (94). In developed countries, the age standardised rates (30-47 per 100,000 in men and 24-31 in women) are typically about four times higher than in some developing countries (rates below 10 per 100,000 for both sexes) (93). The incidence of colorectal cancer is rising in most populations (95).

In most populations, cancer of the colon is more common than that of the rectum (93). The male:female ratio for colon cancer is around unity; and for rectal cancer 1.5 or greater (93). The incidence of colorectal cancer increases with age (93).

Excluding familial adenomatous polyposis or hereditary non-polyposis colorectal cancer, the risks of colorectal cancer to first degree relatives of index patients with the disease is about twice that of the general population (96, 97). The genetic basis of this familial aggregation has not yet been characterised.

Colorectal adenomatous polyps are thought to be precursors of colorectal cancer. While there is no direct evidence in support of the adenoma-carcinoma sequence, there is considerable indirect evidence from a range of epidemiological, histopathological and molecular genetic studies (98).

Exposure of meats to pyrolysis temperatures produces heterocyclic amines and PAHs (99, 100). The World Cancer Research Fund (WCRF) and American Institute of Cancer Research (AICR) panel recently concluded that consumption of red meat "probably" and intake of heavily cooked meats "possibly" increase the risk of colorectal cancer (101). In some studies raised risks of colorectal cancer have been associated with consumption of broiled or grilled meats and browning of the meat surface (102, 103). In a recent study an increase in risk associated with higher levels of both a white meat and an overall meat mutagen index in men was found (104). However, in other studies no association with consumption of broiled or grilled meats or browning of the meat surface was observed (105, 106).

High intakes of alcohol may be associated with increased risk of colorectal lesions (98). With regard to dietary factors which may be protective, the WCRF/AICR panel concluded that there is "convincing" evidence that consumption of vegetables and "possible" evidence that the consumption of non-starch polysaccharides/fibre, starch and carotenoids decrease risk (101). In eight out of twelve studies of colon cancer and all five studies of rectal cancer, high levels of consumption of cruciferous vegetables were associated with decreased risks (101). Cruciferous vegetables may have anti-carcinogenic properties as they contain isothiocyanates which induce enzymes that detoxify environmental mutagens (4, 5).

In addition to diet, the other major environmental source of exposure to PAHs is tobacco smoke. Most studies show a positive association between smoking and colorectal adenomas, but the association between smoking and colorectal cancer is less clear (107). However, in four recent large cohort studies, smoking has been associated with colorectal cancer after a long latent period (108-111).

There is consistent evidence from observational studies that higher levels of physical activity are associated with a reduced risk of colon cancer (112).

While the evidence from observational studies suggests that regular use of aspirin or other non-steroidal-anti-inflammatory drugs reduces the risk for colorectal cancer, no protective effect was found in the intervention trial in which US male physicians were given 325mg aspirin on alternate days or placebo for, on average, five years (113).

Associations

The studies appraised in this section were identified using the search strategy described earlier with the addition of MeSH headings and textwords relevant to colorectal cancer or polyps.

GSTM1 & Colorectal Cancer

The eight available case-control studies of GSTM1 and colorectal cancer (14, 23, 49, 54, 58, 69, 77, 78), and one of colorectal adenomas (114) are summarised in table 4 and discussed below in order of publication. In four, exposure to environmental and lifestyle factors was assessed (14, 58, 69, 114); this is discussed in section 6.

The results of the colorectal cancer studies are inconsistent, three suggesting no association (49, 58, 77), three a slightly lower risk in those with the GSTM1 null genotype (23, 69, 78), and two an increased risk associated with this genotype (14, 54). The study of colorectal adenomas suggests a slightly lower risk in those with GSTM1 null genotype (114).

In the first reported study of colorectal cancer and GSTM1, Zhong et al. (54) found a significantly raised relative risk (RR) associated with the GSTM1 null genotype among 196 cases from an Edinburgh hospital and 225 controls from Sheffield, Edinburgh and Potters Bar (RR=1.8, 95% confidence interval 1.2-2.6). This is the only study in which a statistically significant association was observed. The risk was especially elevated for those with a proximal tumour (RR=3.4; 1.9-6.0).

Chenevix-Trench et al. (78) investigated 132 patients with colorectal adenocarcinoma and 200 controls in Australia. 100 of the controls were "unselected" and no further information on them was presented; the other 100 were geriatric patients without cancer or a family history of cancer. The RR of colorectal cancer associated with the GSTM1 null genotype was 0.9 (0.6-1.4). When the analysis was restricted to cases with a proximal tumour, the RR was also 0.9 (0.4-1.8). The proportions of cases aged less than 70 and over 70 years who were GSTM1 null were not significantly different. The authors acknowledge that their study had fewer cases, a smaller proportion of cases with proximal tumours, and a higher proportion of controls carrying the null genotype than the study of Zhong et al. (54); and hence there may have been inadequate statistical power to detect a relationship of the type observed in the earlier study.

In a Japanese study of 103 consecutive colorectal adenocarcinoma patients, and 126 subjects with no gastrointestinal symptoms or current or previous diagnosis of cancer visiting local medical clinics for regular medical check-ups, a RR of 1.5 (0.9-2.6) associated with the GSTM1 null genotype was observed (14). For proximal cases, the RR was 1.2 (0.6-2.3); and for distal cases the RR was 2.0 (1.0-3.9).

In another study in the UK of 252 colorectal cancer patients, and 577 patients without malignancy or inflammatory pathologies recruited through the same hospital, Deakin et al. (49) found a RR of 1.0 (0.7-1.3) associated with the GSTM1 null genotype. For tumours of the right colon the RR was 0.8 (0.5-1.2), for those of the left colon 1.1 (0.6-1.8) and for the rectum 1.2 (0.8-1.8).

In a study reported only in abstract form, Butler et al. (77) compared the frequency of GSTM1 genotypes between 219 white adults with sporadic colorectal cancer and 200 white blood donors in Australia. The relative risk of colorectal cancer associated with the GSTM1 null genotype was 1.0 (0.7-1.4).

Gertig et al. (58) conducted a case-control study nested within the Physicians’ Health Study (PHS) in the USA. 212 men with colorectal cancer were matched on year of birth and smoking history to men without colorectal cancer. A RR of 1.0 (0.7-1.5) was associated with the GSTM1 null genotype (adjusted for BMI, physical activity and alcohol use). The RRs were not substantially different when the analysis was stratified by age (<=60 years, >60 years). For proximal cancer the adjusted RR was 0.7 (0.4-1.3) and for distal cancer 1.4 (0.8-2.3).

Lee et al. (23) investigated the frequency of GSTM1 polymorphisms among Chinese subjects resident in Singapore. 300 cases of colorectal carcinoma were compared with 183 patients without history of neoplasms recruited from a Clinical Chemistry Department. The RR associated with the GSTM1 null genotype was 0.8 (0.5-1.1). For tumours of the right side the RR was 1.2 (0.6-2.5), for those of the left side 1.0 (0.5-2.1) and for recto-sigmoid tumours 0.7 (0.5-1.0). In individuals with poorly differentiated tumours the frequency of the null genotype was 67%, in moderately differentiated tumors 41% and in well differentiated tumours 43%.

In a large multi-centre case-control study in the USA, Slattery et al. (69) compared 1567 cases and 1889 controls randomly selected from medical care program lists, drivers license lists and social security lists and by random digit dialling. The crude RR for men and women combined of colon cancer associated with the GSTM1 null genotype was 0.9 (0.8-1.1). When the analysis was stratified by age (<67, >=67 years) the RRs were not substantially different. When proximal and distal tumours were considered separately, the crude RRs for both genders combined associated with the GSTM1 null genotype were 1.0 (0.8-1.1) and 0.9 (0.8-1.1) respectively.

In the one study of colorectal adenomatous polyps, from the USA (114), 446 cases were matched on sex, age and date of sigmoidoscopy and centre with 488 controls without colorectal adenomas. The RR associated with the GSTM1 null genotype was 0.9 (0.7-1.1) (adjusted for the matching factors). When the analysis was stratified by ethnic group, the RRs for whites was 1.0 (0.7-1.4), for Hispanics (not black) 0.8 (0.4-1.7), for blacks 0.6 (0.3-1.4) and for Asians and Pacific Islanders 0.4 (0.2-1.1). Cases and controls were identified after sigmoidoscopy. Only the left colon is accessible to sigmoidoscopy, so it is possible that some controls harboured tumours in the rest of their colon – the effect of this would be to bias the RRs towards the null.

GSTT1 & Colorectal cancer

Six of the studies described above also reported GSTT1 genotype (table 5: 14, 23, 49, 58, 77, 78). Two assessed exposure and are discussed in section 6 (14, 58).

The results of these studies are inconsistent. In two studies (49, 77) the GSTT1 null genotype was associated with a statistically significant increase in the risk of colorectal cancer, while in the other four, no noteworthy associations were apparent.

Chenevix-Trench et al. (78) reported a RR for colorectal cancer of 0.9 (0.4-1.7) associated with the GSTT1 null genotype when both the unselected and geriatric controls were considered together. However, when the analysis was repeated using the different control groups separately the RRs were 0.7 (0.3-1.4) (unselected controls) and 1.5 (0.6-4.3) (geriatric controls). This reflects the different proportions of individuals carrying the GSTT1 null genotype in each of the control groups (19% in the unselected controls and 9% in the geriatric controls) and illustrates the potential for selection bias to distort associations between chronic diseases and genetic polymorphisms. Using the unselected and geriatric control groups combined, the RRs associated with the GSTT1 null genotype were 0.4 (0-1.5) for proximal tumours and 1.0 (0.5-2.1) for distal tumours. In those cases who were diagnosed before the age of 70, 21% were homozygous for the GSTT1 null genotype; in those diagnosed at age 70 or older, 7% carried this genotype.

Deakin et al. (49) reported a RR of 1.9 (1.3-2.7) associated with null genotype. They found increased RRs for each of the tumour sub-sites reported: right-sided tumours 1.5 (0.8-2.7), left-sided tumours 2.3 (1.3-4.2) and tumours of the rectum 1.9 (1.1-3.2).

Katoh et al. (14) found a RR of 1.2 (0.7-2.0) for colorectal cancer and Butler et al. (77) report a RR of 3.4 (2.1-5.4) associated with the GSTT1 null genotype. Neither of these studies presented RRs in relation to tumour sub-site.

Gertig et al. (58) reported a RR of colorectal cancer associated with the GSTT1 null genotype of 0.8 (0.5-1.2), adjusted for BMI, physical activity and alcohol use. For proximal tumours the adjusted RR was 0.9 (0.5-1.7) and for distal tumours it was 0.6 (0.3-1.2). In men aged under 60, the RR associated with GSTT1 null genotype was 0.5 (0.2-1.0) and in those aged 60 years or older, the RR was 0.9 (0.5-1.7). It is not clear whether the age-stratified RRs were adjusted.

Lee et al. (23) stated that the frequency of the GSTT1 null genotype was similar in both cases and controls, and that tumour histology had no effect on the frequency of the null genotype. However, insufficient information was presented for a RR to be calculated.

Comment on the studies on GSTM1 and GSTT1 and colorectal cancer

It is difficult to assess how far selection and participation biases may account for the inconsistencies in the results. Most studies involved hospital-based case series and most of the control groups were not population-based. This has implications for the generalisability of the study results. The potential problems of selecting controls who do not represent the population from which cases arose is demonstrated by the divergence in RRs obtained for the GSTT1 null genotype in the study by Chenevix-Trench et al. (78) when the different control groups were analysed. Most of the studies were not large – five included fewer than 250 cases. The smaller studies are likely to have limited statistical power, particularly for sub-group analyses. Two of the studies were undertaken in Asian populations – the others were in predominantly white populations. There is little information available in other ethnic groups. It is unclear whether any of the established risk factors for colorectal cancer are associated with GSTM1 or GSTT1 genotype. The studies made little attempt to adjust for potential confounders.

The findings of these studies require confirmation in other populations.

GSTM1 and other cancers

In a recent review, Rebbeck (6) suggests that there is evidence from case-control studies that GSTM1 is involved in the aetiology of both lung and bladder cancer, although not all studies have shown this. While some studies of other cancer sites have shown an association with GSTM1, these findings have not been confirmed.

GSTT1 and other cancers

There have been fewer case-control studies of GSTT1. Statistically significant associations have been reported for astrocytoma, meningioma and myelodysplasia, but these have not been confirmed (6).

Interactions

Because the GST enzyme family has detoxifying activity it would be expected that, rather than affecting the risk of cancer per se, they would modify risk in relation to exposure to potential carcinogens. The enzymes play a major role in the detoxification of PAHs found in tobacco smoke and in cooked and processed meats. In four studies of colorectal lesions and GSTM1 (14, 58, 69, 114) and two of GSTT1 (14, 58) exposure to tobacco smoke was considered. Meat consumption was considered in relation to GSTM1 in two studies (58, 104), and in relation to GSTT1 in one (58). Consumption of broccoli, the richest source of isothiocyanates, which induce enzymes that detoxify environmental mutagens, was considered in a study of GSTM1 and colorectal adenomas (5). Three studies have considered GST gene-gene interactions and colorectal cancer (23, 58, 69).

The limited statistical power of small studies to detect associations between genotype and disease is particularly important in regard to effect modification. To give adequate statistical power to detect a multiplicative interaction, very large sample sizes (in some circumstances, thousands of cases) may be required (115).

GSTM1 and smoking

Little evidence of interaction between GSTM1 genotype, tobacco exposure and colorectal cancer was found in the three studies (14, 58, 69). However, the one polyp study suggests that GSTM1 genotype may modify the association between smoking and disease (114).

Lin et al. (114) report the effect of cigarette smoking and GSTM1 on adenoma risk. Using the reference group of subjects who were never smokers and were GSTM1 positive, significantly increased adenoma risk were seen in both current smokers who were GSTM1 positive (RR=1.7 (1.0-2.9)) and in current smokers who were GSTM1 null (2.1 (1.1-3.8)). When this analysis was restricted to adenomas >1cm in size, the RRs were 1.3 (0.6-2.9) and 2.5 (1.1-5.5).

Katoh et al. (14) reported that GSTM1 did not influence risk differently in subjects classified by smoking status (smoker or non-smoker) or extent of tobacco exposure (pack-years).

Gertig et al. (58) investigated the joint effect of GSTM1 and cigarette smoking status at entry to the PHS on subsequent risk of colorectal cancer. The RR associated with the GSTM1 null genotype was 1.1 (0.6-2.1) in never smokers; 1.0 (0.6-1.6) in past smokers; and 1.2 (0.3-4.2) in current smokers. There was no significant interaction between pack-years of smoking at baseline and GSTM1 genotype.

In the study of Slattery et al. (69), those who smoked more than a pack per day were at approximately 40% increased risk of colon cancer. No interaction was observed in either men or women between GSTM1 genotype and any of the following categories of tobacco exposure: smoking status, usual number of cigarettes smoked per day, pack-years of cigarettes smoked, age started smoking cigarettes and years since stopped smoking cigarettes.

GSTT1 and smoking

Katoh et al. (14) reported that smoking had no effect on the risk associated with GSTT1 genotypes.

Gertig et al. (58) reported RRs of colorectal cancer associated with the GSTT1 null genotype of 0.8 (0.4-1.8) in those never smokers at the time of enrolment, 0.5 (0.3-1.1) in past smokers, and 1.1 (0.3-4.7) in current smokers. There was no interaction between pack-years of smoking and GSTT1 genotype.

GSTM1 and meat intake

In the study of Gertig et al. (58), men who were homozygous for GSTM1 null and consumed more than one serving of red meat per day were at slightly lower risk compared with men who were not homozygous GSTM1 null and consumed less than 0.5 servings per day (RR=0.8 (0.4-2.0)).

Kampmann et al. (104) reported associations between GSTM1 genotype and various measures of meat consumption in the subjects investigated by Slattery et al. (69). There was no evidence that GSTM1 genotype modified the RRs associated with amount of (a) red meat (b) processed meat or (c) poultry consumed; (d) frequency of fried, broiled, baked or barbecued red meat; (e) preferred "doneness" of red meat; frequency of use of (f) red meat or (g) white meat drippings; or (h) red meat mutagen index. GSTM1 genotype modified risks associated with frequency of fried, broiled, baked or barbecued white meat; white meat mutagen index; and total meat mutagen index. Unexpectedly, the strongest positive associations were observed among those who were GSTM1 positive.

GSTT1 and meat intake

In the PHS, men who were GSTT1 null homozygous and consumed more than one serving of red meat daily had a lower risk compared with men who were GSTT1 non-null and consumed less than 0.5 servings daily (RR=0.4 (0.1-1.4)) (58).

GSTM1 and isothiocyanates

Lin et al. (5) postulated that a cancer preventive effect of broccoli would be stronger in GSTM1 null individuals and investigated this in the subjects investigated earlier by Lin et al. (114). Compared to subjects in the lowest quartile of broccoli intake who were GSTM1 null, those in the highest intake quartile who were null had a RR of 0.36 (0.19-0.68) and those in the highest intake quartile who were GSTM1 positive had a RR of 0.74 (0.40-0.99); this interaction was statistically significant (p=0.01).

GSTM1, GSTT1, and other genes

In the PHS, there was no increased risk of colorectal cancer in men who were homozygous null for both GSTM1 and GSTT1 compared to those who were homozygous positive for both GSTM1 and GSTT1 (58). By contrast, Lee et al. (23) reported that 35% of cases with right sided tumours were GSTM1 null and GSTT1 positive compared to 22% of the control series.

Slattery et al. (69) considered the possibility of an interaction between GSTM1 and N-acetyltransferase 2 (NAT2) genotypes. There was a suggestion that women with the combined NAT2 intermediate/rapid and GSTM1 positive genotypes were at increased risk compared to those NAT2 slow/GSTM1 positive genotypes (unadjusted RR=1.5 (1.11-2.05)). This was restricted to women older than 67 and with proximal tumours. However, the association was weaker and not statistically significant in men (unadjusted RR=1.2 (0.89-1.51)). There was no strong evidence of any interaction between NAT2, GSTM1 and smoking in either men or women.

Laboratory Tests

To classify an individual as GSTM1 null or non-null (or GSTT1 null or non-null), the genotyping procedure detects either the absence or the presence of the GSTM1 (or the GSTT1) gene. Therefore after the gene has been amplified by PCR methods, the product needs only to be visualised. This method can not, however, distinguish between the GSTM1*A and GSTM1*B alleles. To do this, a restriction digest must be undertaken. This cleaves the DNA into fragments of characteristic sizes, and the different combinations of these fragments correspond to specific alleles.

To ensure a PCR reaction occurred, a number of quality control procedures should undertaken. Additional "control" primers should be added. These amplify another region of DNA (one that is thought never to be deleted) to confirm that amplification has worked in null individuals. Alongside the samples being amplified, a positive and negative control should be run. The positive control is a sample of DNA known to contain the gene (ie not null); both the band representing the gene in question and the control band should be visible in order for the genotyping to be validated. The negative control allows a check for contamination to be made; if amplification is seen in this control, the samples run at the same time should not be genotyped. In general, the studies present little information on the proportion of subjects for whom genotype could be determined, or reproducibility of genotyping.

Much of the PCR work on genotyping has used DNA from blood; however work involving DNA from mouthwash samples is now being undertaken (116). This development makes PCR methodology even more appropriate for researchers undertaking molecular epidemiology studies, as it enables subjects to be genotyped without the need for invasive sampling.

GSTM1

In two of the nine studies of GSTM1 and colorectal lesions, no details of the primers used are given (23, 77). Three studies (58, 78, 114) use the same primers to amplify the GSTM1 gene, although they reference different papers for these methods (64, 89, 117). The primer 5’-CTGCCCTACTTGATTGATGGG-3’ anneals to the 5’ region of exon 4 and the primer 5’-CTGGATTGTAGCAGATCATGC-3’ anneals to the 3’ region of exon 5. They amplify a 273 bp product, but use slightly different amplification cycles. Katoh et al. (14) used the method outlined by Bell et al. (67). The primers are 5’-GAACTCCCTGAAAAGCTAAAGC-3’ and 5’-GTTGGGCTCAAATATACGGTGG-3’; and they amplify a 215 bp product. The amplification cycles are undertaken at similar temperatures to Comstock et al. (117) and Brockmöller et al. (89), but the time for each stage of the cycle is considerably shorter, and there are fewer cycles in total.

Deakin et al. (49) used the methods of Warwick et al. (84) and Fryer et al. (118) where three primers (5’-GCTTCACGTGTTATGAAGGTTC-3’, 5’-TTGGGAAGGCGTCCAAGCGC-3’, 5’-TTGGGAAGGCGTCCAAGCAG-3’) are used to amplify DNA in intron 6 and exon 7 and a restriction digest differentiates alleles GSTM1*A and GSTM1*B (118). Slattery et al. (69) use the method outlined by Zhong et al. (54) where three primers (P1 5’-CGCCATCTTGTGCTACATTGCCCG-3’, P2 5’-ATCTTCTCCTCTTCTGTCTC-3’, P3 5’-TTCTGGATTGTAGCAGATCA-3’) are combined in a single PCR. Primers P1 and P3 amplify a 230 bp product specific to GSTM1; primers P1 and P2 anneal to either GSTM1 or GSTM4 and amplify a 157 bp product, thereby acting as the control primers.

In another two studies, explicit mention is made of the use of control primers: Chenevix-Trench et al. (78) used primers for exon 1 of coagulation factor XIII and Katoh et al. (14) used primers for beta-globin. In the methodology of Warwick et al (84) – used by Deakin et al. (49) beta-globin is again used as the control primer. In two studies (14, 58) the use of positive and negative controls samples is reported.

GSTT1

In two of the six studies (23, 77) no details on the methods used are given. In the other four (14, 49, 58, 78) the genotyping methods outlined by Pemble et al. (91) were employed. The primers used for amplification in this method are TTCCTTACTGGTCCTCACATCTC and TCACCGGATCATGGCCAGCA. In two studies the use of control primers is described: Chenevix-Trench et al. (78) used primers for GSTP1 and Katoh et al. (14) used primers for beta-globin. In two studies (14, 58) the use of positive and negative controls samples is mentioned.

Population Testing

To date, there is insufficient evidence implicating GSTM1 or GSTT1 in the aetiology of colorectal neoplasms to make population testing an issue.

References

  1. Hayes, J.D. & Pulford, D.J. The glutathione S-transferase supergene family: Regulation of GST* and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical Reviews in Biochemistry and Molecular Biology 1995;30:445-600.
  2. Rushmore, T.H. & Pickett, C.B. Glutathione S-Transferases, structure, regulation, and therapeutic implications. Journal of Biological Chemistry 1993;268:11475-78.
  3. Hirvonen, A. Genetic factors in individual responses to environmental exposures. Journal of Occupational and Environmental Medicine 1995;37:37-43.
  4. Prochaska, H.J., Santamaria, A.B. & Talalay, P. Rapid detection of inducers of enzymes that protect against carcinogens. Proceedings of the National Academy of Sciences of United States of America 1992;89:2394-8.
  5. Lin, H.J., Probst-Hensch, N.M., Louie, A.D. et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiology, Biomarkers & Prevention 1998;7:647-52.
  6. Rebbeck, T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiology, Biomarkers & Prevention 1997;6:733-43.
  7. Anwar, W.A., Abdel-Rahman, S.Z., El-Zein, R.A. et al. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996;17:1923-9.
  8. Abdel-Rahman, S.Z., El-Zein, R.A., Anwar, W.A. et al. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Letters 1996;107:229-33.
  9. McGlynn, K.A., Rosvold, E.A., Lustbader, E.D. et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proceedings of the National Academy of Sciences of United States of America 1995;92:2384-7.
  10. Masimirembwa, C.M., Dandara, C., Sommers, D.K. et al. Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of Southern Africa. Pharmacogenetics 1998;8:83-5.
  11. Hung, H.C., Chuang, J., Chien, Y.C. et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; Environmental factors and risk of oral cancer. Cancer Epidemiology, Biomarkers & Prevention 1997;6:901-5.
  12. Rothman, N., Hayes, R.B., Zenser, T.V. et al. The glutathione S-transferase M1 (GSTM1) null genotype and benzidine-associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adducts. Cancer Epidemiology, Biomarkers and Prevention 1996;5:979-83.
  13. Lin, H.J., Han, C.Y., Bernstein, D.A. et al. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994;15:1077-81.
  14. Katoh, T., Nagata, N., Kuroda, Y. et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996;17:1855-9.
  15. Kihara, M., Noda, K. & Okamoto, N. Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Letters 1993;71:151-5.
  16. Kihara, M., Kihara, M. & Noda, K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994;15:415-8.
  17. Morita, S., Yano, M., Shiozaki, H. et al. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. International Journal of Cancer 1997;71:192-5.
  18. Nakachi, K., Imai, K., Hayashi, S. et al. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Research 1993:53;2994-9.
  19. Kato, S., Onda, M., Matsukura, N. et al. Genetic polymorphisms of the cancer related gene and helicobacter pylori infection in Japanese gastric cancer patients. Cancer 1996;77:1654-61.
  20. Hori, H., Kawano, T., Endo, M. et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. Journal of Clinical Gastroenterology 1997;25:568-75.
  21. Zhao, B., Lee, E.J.D., Wong, J.Y.Y. et al. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 1995;5:275-80.
  22. Lee, E.J.D., Zhao, B., Moochhala, S.M. et al. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in a normal Chinese population. Pharmacogenetics 1994;4:355-8.
  23. Lee, E., Huang, Y., Zhao, B. et al. Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. Journal of Toxicological Sciences 1998;23:140-2.
  24. Yu, M.W., Gladek-Yarborough, A., Chiamprasert, S. et al. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-73.
  25. Okkels, H., Sigsgaard, T., Wolf, H. et al. Glutathione S-transferase mu as a risk factor in bladder tumours. Pharmacogenetics 1996;6;251-6.
  26. Vistisen, K., Priemé, H., Okkels, H. et al. Genotype and phenotype of glutathione S-transferase mu in testicular cancer patients. Pharmacogenetics 1997;7:21-5.
  27. Mikelsaar, A.V., Tasa, G., Parlist, P. et al. Human glutathione S-transferase GSTM1 genetic polymorphism in Estonia. Human Heredity 1994;44:248-51.
  28. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S. et al. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993;14:1479-81.
  29. Jourenkova, N., Reinikanen, M., Bouchardy, C. et al. Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on lung cancer risk in smokers. Pharmacogenetics 1997;7:515-8.
  30. Coutelle, C., Ward, P.J., Fleury, B. et al. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Human Genetics 1997;99:319-25.
  31. Maugard, C.M., Charrier, J. & Bignon, Y.J. Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility. Chemico-Biological Interactions 1998;111-112:365-75.
  32. Jahnke, V., Matthias, C., Fryer, A. et al. Glutathione S-transferase and cytochrome P450 polymorphism as risk factors for squamous cell carcinoma of the larynx. American Journal of Surgery 1996;172:671-3.
  33. Brockmöller, J., Kerb, R., Drakoulis, N. et al. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Research 1993;53:1004-11.
  34. Brockmöller, J., Kerb, R., Drakoulis, N. et al. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: A case-control study. Cancer Research 1994;54:4103-11.
  35. Kempkes, M., Golka, K., Reich, S. et al. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Archives of Toxicology 1996;71:123-6.
  36. Brockmöller, J., Cascorbi, I., Kerb, R. et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Research 1996;56:3915-25.
  37. Oude Ophuis, M.B., van Lieshout, E.M.M., Roelofs, H.M.J. et al. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998;82:936-43.
  38. Moreira, A., Martins, G., Monteiro, M.J. et al. Glutathione S-transferase mu polymorphism and susceptibility to lung cancer in the Portuguese population. Teratogenesis Carcinogenesis and Mutagenesis 1996;16:269-74.
  39. Esteller, M., Garcia, A., Martinez-Palones, J.M. et al. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. British Journal of Cancer 1997;75:1385-8.
  40. Gonzalez, M.V., Alvarez, V., Pello, M.F. et al. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. Journal of Clinical Pathology 1998;51:294-8.
  41. Alexandrie, A.K., Sundberg, M.I., Seidegård, J. et al. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994;15:1785-90.
  42. Ichiba, M., Hagmar, L., Rannug, A. et al. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GST1 in chimney sweeps. Carcinogenesis 1994;15:1347-52.
  43. Warholm, M., Alexandrie, A.K., Högberg, J. et al. Polymorphic distribution of glutathione transferase activity with methyl chloride in human blood. Pharmacogenetics 1994;4:307-11.
  44. Fryer, A.A., Zhao, L., Alldersea, J. et al. The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. Carcinogenesis 1993;14:563-6.
  45. Chern, H.D., Romkes-Sparks, M., Hu, J.J. et al. Homozygous deleted genotype of glutathione S-transferase M1 increases susceptibility to aggressive bladder cancer. Proceedings of the American Association for Cancer Research 1994;35:285.
  46. Daly, A.K., Thomas, D.J., Cooper, J. et al. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. British Medical Journal 1993;307:481-2.
  47. Duncan, H., Swan, C., Green, J. et al. Susceptibility to ulcerative colitis and Crohn's disease: interactions between glutathione S-transferase GSTM1 and GSTT1 genotypes. Clinica Chimica Acta 1995;240:53-61.
  48. Elexpuru-Camiruaga, J., Buxton, N., Kandula, V. et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Research 1995;55:4237-9.
  49. Deakin, M., Elder, J., Hendrickse, C. et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881-4.
  50. Inskip, A., Elexperu-Camiruaga, J., Buxton, N. et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochemical Journal 1995;312:713-6.
  51. Hand, P.A., Inskip, A., Gilford, J. et al. Allelism at the glutathione S-transferase GSTM3 locus: interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis 1996;17:1919-22.
  52. Yengi, L., Inskip, A., Gilford, J. et al. Polymorphism at the glutathione S-transferase locus GSTM3: Interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Research 1996;56:1974-77.
  53. Sarhanis, P., Redman, C., Perrett, C. et al. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression. British Journal of Cancer 1996;74:1757-61.
  54. Zhong, S., Wyllie, A.H., Barnes, D. et al. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993;14:1821-4.
  55. Heagerty, A., Smith, A., English, J. et al. Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM1 genotypes, skin type and male gender. British Journal of Cancer 1996;73:44-8.
  56. Heagerty, A.H.M., Fitzgerald, D., Smith, A. et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994;343:266-8.
  57. Kelsey, K.T., Hankinson, S.E., Colditz, G.A. et al. Glutathione S-transferase class m deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiology, Biomarkers & Prevention 1997;6:511-5.
  58. Gertig, D.M., Stampfer, M., Haiman, C.H. et al. Glutathione S-Transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: a prospective study. Cancer Epidemiology, Biomarkers and Prevention 1998;7:1001-5.
  59. Chen, C.L., Liu, Q. & Relling, M.V. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996;6:187-91.
  60. García-Closas, M., Kelsey, K.T., Wiencke, J.K. et al. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes and Control 1997;8:544-53.
  61. London, S.J., Daly, A.K., Cooper, J. et al. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. Journal of the National Cancer Institute 1995;87:1246-53.
  62. Yu, M.C., Ross, R.K., Chan, K.K. et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiology, Biomarkers and Prevention 1995;4:861-4.
  63. Helzlsouer, K.J., Selmin, O., Huang, H.Y. et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. Journal of the National Cancer Institute 1998;90:512-8.
  64. Cheng, T.J., Christiani, D.C., Xu, X. et al. Glutathione S-transferase mu genotype, diet, and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epidemiology, Biomarkers and Prevention 1995;4:535-542.
  65. Bailey, L.R., Roodi, N., Verrier, C.S. et al. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in caucasians and African Americans. Cancer Research 1998;58:65-70.
  66. Ambrosone, C.B., Freudenheim, J.L., Graham, S. et al. Cytochrome P4501A1 and Glutathione S-Transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Research 1995;55:3483-5.
  67. Bell, D.A., Taylor, J.A., Paulson, D.F. et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. Journal of the National Cancer Institute 1993;85:1159-64.
  68. Chen, H., Sandler, D.P., Taylor, J.A. et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996;347:295-7.
  69. Slattery, M.L., Potter, J.D., Samowitz, W. et al. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiology, Biomarkers & Prevention 1998;7:1079-84.
  70. Park, J.Y., Muscat, J.E., Fen, Q. et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiology, Biomarkers and Prevention 1997;6:791-7.
  71. Wiencke, J.K., Wrensch, M.R., Miike, R. et al. Population-based study of glutathione S-transferase mu gene deletion in adult glioma cases and controls. Carcinogenesis 1997;18:1431-3.
  72. Nazar-Stewart, V., Motulsky, A.G., Eaton, D.L. et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Research 1993;53:2313-8.
  73. Trizna, Z., Clayman, G.L., Spitz, M.R. et al. Glutathione S-transferase genotypes as risk factors for head and neck cancer. American Journal of Surgery 1995;170:499-501.
  74. Kelsey, K.T., Spitz, M.R., Zuo, Z.F. et al. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes and Control 1997;8:554-9.
  75. Trizna, Z., de Andrade, M., Kyritsis, A.P. et al. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiology, Biomarkers and Prevention 1998;7:553-5.
  76. Chen, C., Madeleine, M.M., Lubinski, C. et al. Glutathione S-transferase M1 genotypes and the risk of anal cancer: a population-based case-control study. Cancer Epidemiology, Biomarkers and Prevention 1996;5:985-91.
  77. Butler, W.J., Ryan, P. & Roberts-Thomson, I.C. Metabolic genotypes and risk for colorectal cancer increased risk in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Gastroenterology 1997;112:A542.
  78. Chenevix-Trench, G., Young, J., Coggan, M. et al. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis 1995;16:1655-7.
  79. Board, P., Coggan, M., Johnston, P. et al. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacology and Therapeutics 1990;48:357-69.
  80. Nelson, H.H., Wiencke, J.K., Christiani, D.C. et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16:1243-5.
  81. Lee, E.J., Wong, J.Y., Yeoh, P.N. et al. Glutathione S transferase-theta (GSTT1) genetic polymorphism among Chinese, Malays and Indians in Singapore. Pharmacogenetics 1995;5:332-4.
  82. Kempkes, M., Wiebel, F.A., Golka, K. et al. Comparative genotyping and phenotyping of glutathione S-transferase GSTT1. Archives of Toxicology 1996;70:306-9.
  83. Warholm, M., Rane, A., Alexandrie, A.K. et al. Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. Pharmacogenetics 1995;5:252-4.
  84. Warwick, A., Sarhanis, P., Redman, C. et al. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. Carcinogenesis 1994;15:2841-5.
  85. Wiencke, J.K., Pemble, S., Ketterer, B. et al. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiology, Biomarkers and Prevention 1995;4:253-9.
  86. Garte, S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19:1329-32.
  87. Shea, T.C., Claflin, G., Comstock, K.E. et al. Glutathione transferase activity and isoenzyme composition in primary human breast cancers. Cancer Research 1990;50:6848-53.
  88. Zhong, S., Howie, A.F., Ketterer, B. et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991;12:1533-7.
  89. Brockmöller, J., Gross, D., Kerb, R. et al. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class Mu gene detected by polymerase chain reaction. Biochemical Pharmacology 1992;43:647-50.
  90. Mukanganyama, S., Masimirembwa, C.M., Naik, Y.S. et al. Phenotyping of the glutathione S-transferase M1 polymorphism in Zimbabweans and the effects of chloroquine on blood glutathione S-transferases m1 and A. Clinica Chimica Acta 1997;265:145-55.
  91. Pemble, S., Schroeder, K.R., Spencer, S.R. et al. Human glutathione S-transferase q (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochemical Journal 1994;300:271-6.
  92. WHO (World Health Organization). The World Health Report 1997: Conquering suffering, enriching humanity. Geneva: World Health Organization, 1997.
  93. Parkin, D.M., Whelan, S.L., Ferlay, J. et al. Cancer Incidence in Five Continents. Volume VII. (IARC Scientific Publication No. 143). Lyon: IARC, 1997.
  94. Parkin, D.M., Pisani, P. & Ferlay, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. International Journal of Cancer 1993;54:594-606.
  95. Coleman, M.P., Estève, J., Damiecki, P. et al. Trends in Cancer Incidence and Mortality. (IARC Scientific Publication No. 121). Lyon: IARC, 1993.
  96. St John, D.J.B., McDermott, F.T., Hopper, J.L. et al. Cancer risk in relatives of patients with common colorectal cancer. Annals of Internal Medicine 1993;118:785-90.
  97. Fuchs, C.S., Giovannucci, E.L., Colditz, G.A. et al. A prospective study of family history and the risk of colorectal cancer. New England Journal of Medicine 1994;331:1669-74.
  98. Cotton, S., Sharp, L. & Little, J. The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. Critical Reviews in Oncogenesis 1996;7(5&6):293-342.
  99. Vineis, P. & McMichael, A. Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Cancer Causes and Control 1996;7:479-86.
  100. Sivaraman, L., Leatham, M.P., Yee, J. et al. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Research 1994;54:3692-5.
  101. World Cancer Research Fund in Association with American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: a global perspective. Menasha: American Institute for Cancer Research, 1997.
  102. Schiffman, M.H. & Felton, J.S. Re: "Fried foods and the risk of colon cancer". American Journal of Epidemiology 1990;131:376-9.
  103. Gerhardsson De Verdier, M., Hagman, U., Peters, R.K. et al. Meat, cooking methods and colorectal cancer: A case-referent study in Stockholm. International Journal of Cancer 1991;49:520-5.
  104. Kampman, E., Slattery, M.L., Bigler, J. et al. Meat consumption, genetic susceptibility, and colon cancer risk: A United States multicenter case-control study. Cancer Epidemiology, Biomarkers and Prevention 1999;8:15-24.
  105. Lyon, J.L. & Mahoney, A.W. Fried foods and the risk of colon cancer. American Journal of Epidemiology 1988;128:1000-5.
  106. Muscat, J.E. & Wynder, E.L. The consumption of well-done red meat and the risk of colorectal cancer. American Journal of Public Health 1994;84:856-8.
  107. Nyrén, O., Bergström, R., Nyström, L. et al. Smoking and colorectal cancer: a 20-year follow-up study of Swedish construction workers. Journal of the National Cancer Institute 1996;88:1302-7.
  108. Giovannucci, E., Colditz, G.A., Stampfer, M.J. et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US women. Journal of the National Cancer Institute 1994;86:192-9.
  109. Giovannucci, E., Rimm, E.B., Stampfer, M.J. et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US men. Journal of the National Cancer Institute 1994;86:183-91.
  110. Heineman, E.F., Zahm, S.H., McLaughlin, J.K. et al. Increased risk of colorectal cancer among smokers: Results of a 26-year follow-up of US veterans and a review. International Journal of Cancer 1995;59:728-38.
  111. Knekt, P., Hakama, M., Jarvinen, R. et al. Smoking and risk of colorectal cancer. British Journal of Cancer 1998;78:136-9.
  112. Surgeon General. Physical Activity and Health. A Report of the Surgeon General. Washington, D.C.: US Department of Health and Human Services, 1996.
  113. IARC Working Group. IARC Handbook of Cancer Prevention, Volume 1: Non-Steroidal Anti-Inflammatory Drugs. Lyon: IARC, 1997.
  114. Lin, H.J., Probst-Hensch, N.M., Ingles, S.A. et al. Glutathione transferase (GSTM1) null genotype, smoking and prevalence of colorectal adenomas. Cancer Research 1995;55:1224-6.
  115. Smith, P.G. & Day, N.E. The design of case-control studies: the influence of confounding and interaction effects. International Journal of Epidemiology 1984;13:356-65.
  116. Howe, J., Little, J., Cassidy, J. et al. Colorectal cancer, dietary folate and MTHFR polymorphism: a pilot study. In: Abstracts from 2nd Nottingham International Colorectal Cancer Symposium, 23rd-24th October 1997. University of Nottingham, England, 1997:37.
  117. Comstock, K.E., Sanderson, B.J.S., Claflin, G. et al. GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Research 1990;18:3670.
  118. Fryer, A.A., Zhao, L., Alldersea, J. et al. Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochemical Journal 1993;295:313-5.

Tables 1 - 5 - Available in the following format:

Figure 1

Internet Sites 

Data on Disease Frequency

General Information on Cancer

Gene Specific Information

GSTM1

GSTT1


read.gif (1445 bytes) Medical Literature Search

Home | About HuGE | What's New?Reviews & Links | Pub Lit Database | CDC Genomics | Disclaimer